Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Alternative Names: CRM1-mediated nuclear export inhibitors - Karyopharm; KPT-185; KPT-SINE; SINE™ compounds; XPO1-mediated nuclear export inhibitors - Karyopharm

Latest Information Update: 28 Apr 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Karyopharm Therapeutics
  • Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Antivirals; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Exportin 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; HIV infections; Inflammation; Influenza virus infections; Wounds

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Amyotrophic lateral sclerosis; Autoimmune disorders; Brain injuries; Cancer; Duchenne muscular dystrophy; Epilepsy; HIV infections; Inflammation; Multiple sclerosis; Skin disorders; Wounds

Most Recent Events

  • 28 Apr 2021 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (PO)
  • 28 Apr 2021 No recent reports of development identified for preclinical development in Epilepsy in USA (PO)
  • 28 Oct 2019 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top